
Fractyl reports 7.8% weight regain with Revita
- Fractyl Health reported 7.8% weight regain with Revita versus 13% with sham after one year.
- Fractyl shares rose 5% to $0.84 following the clinical data announcement.
- The company expects Pivotal Cohort data in early Q4 2026 and could submit an FDA De Novo application in late Q4.
Fractyl Health (NASDAQ:GUTS) reported one-year REMAIN-1 data showing 7.8% weight regain with Revita versus 13% with sham in 45 participants.
The randomized, double-blind study evaluated adults who lost at least 15% of their body weight with tirzepatide before discontinuing treatment.
Participants receiving more than 14 centimetres of duodenal ablation maintained about 81% of prior weight loss, while adverse-event rates were 24% with Revita and 25% with sham.
Following the announcement, Fractyl Health's share price was up 5% at $0.84.
Fractyl’s earlier REVEAL-1 open-label study found participants maintained about 78% of GLP-1-induced weight loss one year after receiving Revita.
Fractyl expects six-month Pivotal Cohort data in early Q4 2026 and said a potential FDA De Novo application could follow in late Q4 2026.
Frequently asked questions
More from United States
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab
DataMeds AI issues 630,000 shares in cancer partnership
CoinShares net income improves 27% to $39.6 million
newcleo revenue skyrockets 26% to €10 million in Q3